Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3034 |
|
| Actual shortage: | 241 (8%) | |
| Anticipated shortage: | 18 (1%) | |
| Avoided shortage: | 9 (0%) | |
| Resolved: | 2766 (91%) | |
Discontinuation Reports |
356 |
|
| To be discontinued: | 22 (6%) | |
| Discontinued: | 334 (94%) | |
| Reversed: | 0 (0%) | |
Late reports |
142 (4%) |
|
Overdue reports |
30 (11%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2020-11-26 | 2020-12-17 | 128933 |
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2021-02-19 | 2021-03-15 | 134433 |
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-01-26 | 2023-02-23 | 182382 |
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-06-09 | 2023-09-22 | 194571 |
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-10-06 | 2024-02-16 | 206563 |
| APO-GLICLAZIDE MR | 60MG | TABLET (EXTENDED-RELEASE) | Actual shortage | 2024-01-26 | 2024-03-27 | 217481 |
| APO-GLICLAZIDE MR | 30MG | TABLET (EXTENDED-RELEASE) | Actual shortage | 2024-04-19 | 2024-04-26 | 225793 |
| APO-GLIMEPIRIDE | 4MG | TABLET | Resolved | 2017-11-28 | 2019-09-21 | 31007 |
| APO-GLIMEPIRIDE | 1MG | TABLET | Resolved | 2017-12-12 | 2019-09-21 | 32536 |
| APO-GLIMEPIRIDE | 2MG | TABLET | Resolved | 2018-07-11 | 2019-09-21 | 55281 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-06-12 | 2022-07-28 | 162475 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-11 | 2022-08-12 | 164378 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-22 | 2022-08-06 | 165317 |
| APO-GUANFACINE XR | 4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-07-22 | 2022-08-06 | 165322 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-10-06 | 2024-01-12 | 206579 |
| APO-GUANFACINE XR | 1MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-11-06 | 2024-01-12 | 209339 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-08 | 2024-01-12 | 212949 |
| APO-GUANFACINE XR | 4MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-15 | 2024-01-12 | 213559 |
| APO-GUANFACINE XR | 3MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-22 | 2024-01-12 | 214220 |
| APO-GUANFACINE XR | 2MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-22 | 2024-01-12 | 214232 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BROMAZEPAM | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60335 |
| APO-CAPTO TAB 6.25MG | 6.25MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60339 |
| APO-CARVEDILOL | 12.5MG | TABLET | To be discontinued | 2024-01-26 | 2024-04-01 | 217493 |
| APO-CARVEDILOL | 3.125MG | TABLET | To be discontinued | 2024-01-26 | 2024-01-26 | 217496 |